Pharmaceuticals, Biotechnology and Life Sciences
Futura Medical’s pivotal efficacy study of MED2002, a novel gel for the treatment of erectile dysfunction (ED) is underway and recruitment of patients for the study is proceeding well, with 118 patients having enrolled in the study to date.
Faron Pharmaceuticals Oy (Faron), the clinical stage biopharmaceutical company, has started dealing its Ordinary Shares on the AIM market of the London Stock Exchange with effect from 8.00 a.m. Tuesday after placing and subscription for 3,846,154 new Ordinary Shares, raising £10.0 million at a price of 260p per ordinary.
A Roche drug that can prolong the lives of some women with advanced breast cancer has been plunged back into the centre of a drug pricing row after Britain’s health cost agency declared that it is still too expensive.
A single dose of Bimatoprost Sustained-Release (SR) lowered intraocular pressure (IOP) in 92 percent (n= 69) of glaucoma patients at 4 months and 71 percent (n=53) at 6 months while demonstrating a favorable efficacy and safety profile.
The National Health Service (NHS) in England has more than doubled funding from £15m to £31m for its clinical pharmacists in general practice pilot, due to an overwhelmingly positive response from GP surgeries.
LEO Pharma and Japanese pharmaceutical company Astellas Pharma Inc. have entered into an Asset Purchase Agreement under which Astellas will transfer its global dermatology business to LEO Pharma for € 675 million.
Dublin-based Horizon Pharma has provided an update on shareholders meeting related to the proposed acquisition of Depomed, Inc., according to which shareholders approved the issuance of up to 81,706,881 ordinary shares of Horizon Pharma plc, in connection with an acquisition of Depomed, Inc.
Novartis’ division and eye care specialist Alcon, is introducing its latest advancement in its WaveLightrefractive portfolio Contoura Vision.
Roche’s Media Spokesperson, Dr. Ulrike Engels-Lange, said in an email sent to Pharmaceutical Daily that the site exits are expected to affect approximately 1,200 positions.
Turing Pharmaceuticals AG, a privately-held biopharmaceutical company focused on developing and commercializing innovative treatments for serious diseases and conditions, reported net revenue $5.6 million for the third quarter 2015.